Psittacosis Treatment Market : Global Share, Size, Growth, Trends & Outlook ( 2022 – 2032 )

Healthcare & Pharmaceutical

Request PDF Sample Request Discount
  • Status : Published
  • Published on: Feb 2023
  • Report ID: KDMI-7152
  • Available Format: PDF/Excel/DOC


Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Psittacosis Treatment Market

Request PDF Sample

Psittacosis Treatment Market Key Findings:

  • The demand for psittacosis treatments is rising as a result of the disease's potential to spread from birds to humans.
  • Antibiotics like macrolides and tetracyclines, which are widely used to treat infections, dominate the global market. Their expansion is being fuelled by the increased number of individuals purchasing pet birds, especially parakeets, and parrots.
  • It is also anticipated that increasing public awareness of psittacosis and its symptoms will encourage the market's expansion.
  • On the other hand, it's projected that the market's growth would be constrained by the expensive nature of therapy and the accessibility of substitute methods.
  • An rise in psittacosis epidemics in the poultry sector is anticipated, which will further fuel market expansion.
  • Due to the rising popularity of pet birds there and increased knowledge of psittacosis, the Asia-Pacific region is anticipated to see the highest growth throughout the projected period.


Psittacosis Treatment Market Insights:

Psittacosis Understanding and Treatment Algorithm

Psittacosis is a bacterial infection caused by Chlamydia psittaci. It is also known as parrot fever or avian chlamydiosis. Inhaling the respiratory secretions or dust of infected birds, such as parrots, parakeets, and other pet birds is the primary method of transmission.

Psittacosis can cause a variety of symptoms, including a dry cough, headache, muscle aches, and fever. The disease can also lead to severe or even life-threatening pneumonia in some cases. Testing in the laboratory, such as cultures and blood tests, is used to make the diagnosis of psittacosis.

Antibiotics, such as tetracyclines or macrolides, are typically included in the psittacosis treatment regimen because of their effectiveness in eliminating the infection. Patients with severe cases or immunocompromised patients may require treatment for longer than 14 days. Patients should also be told not to touch birds and to take precautions to avoid getting sick, like wearing a mask when cleaning cages or handling birds.

In general, excellent supportive care is crucial. For severe conditions or patients at high risk for complications, hospitalization may be necessary in some instances. It is essential to keep in mind that Psittacosis is a disease that must be reported to public health authorities in order to prevent the disease's spread.



Psittacosis treatment emerging drugs

Psittacosis-specific medications have not yet been approved by the FDA. Antibiotics like tetracyclines (doxycycline) and macrolides (azithromycin, erythromycin), which have been used for decades, are the standard treatment for psittacosis.

However, new medications and treatments for psittacosis are currently being developed and researched:

  1. A protein-based therapeutic vaccine that aims to induce an immune response against Chlamydia psittaci is under development.
  2. A novel antibiotic, called retapamulin, is being studied as a potential treatment for psittacosis, as it has been shown to be effective against Chlamydia psittaci in in-vitro studies.
  3. Some studies have suggested that the use of probiotics as an adjunctive treatment to antibiotics may improve the cure rate of psittacosis.


Psittacosis Treatment Market

Because psittacosis is uncommon and typically responds well to antibiotic treatment, the market for its treatment is relatively small. There were 86 reported cases of psittacosis in the United States between 2014 and 2018, according to a report from the Centers for Disease Control and Prevention (CDC). This indicates that there is a relatively small market for treatments for psittacosis. Tetracyclines like doxycycline and macrolides like azithromycin are the antibiotics used most frequently to treat psittacosis. Doxycycline, Azithromycin, and Erythromycin are a few of these antibiotics' most common brand names. These antibiotics are available in a variety of forms, including oral suspensions, tablets, and capsules.


Psittacosis Treatment Market Driving Factors:

Several factors are driving the growth of the psittacosis treatment market:

  1. Advancements in diagnostic technologies: Modern diagnostic methods like polymerase chain reaction (PCR) testing have made it easier and quicker to diagnose psittacosis. More prompt therapy has resulted in better patient outcomes.
  2. Government initiatives: In addition, it is anticipated that the government's efforts to prevent the spread of psittacosis will fuel market expansion. These efforts include establishing public health initiatives and regulations to ensure the safe handling of birds.
  3. Growing awareness among healthcare professionals: Healthcare practitioners are becoming more aware of the symptoms and indications of psittacosis as well as the necessity for quick diagnosis and treatment due to the rising demand for the medication.
  4. Growing awareness and incidence: The increasing awareness about psittacosis and its symptoms is also expected to drive market growth. As the incidence of psittacosis rises, so does the need for effective treatments. The Centers for Disease Control and Prevention (CDC) reported 269 cases of psittacosis in the United States between 2010 and 2018.
  5. Growing number of avian clinics: The rise in avian clinics and veterinary hospitals is also anticipated to fuel market expansion.
  6. High cost of treatment: Due to people's willingness to spend more on therapy, the market is anticipated to rise as a result of the high cost of treatment.
  7. Increase in outbreaks of Psittacosis in the poultry industry: Market expansion is also anticipated to be driven by the rising number of psittacosis outbreaks in the poultry industry.
  8. Increasing pet ownership: In general, a greater number of people own pets, particularly birds. The possibility that psittacosis can spread from birds to humans is driving up the need for treatments.


Psittacosis Treatment Market Segmentation:

The Psittacosis Treatment market can be segmented based on the followings:

  1. By Drug class: Macrolides, Tetracyclines, Fluoroquinolones
  2. By Route of administration: Oral, Intravenous, Intramuscular
  3. By End-user: Hospitals, Clinics, Home Care
  4. By Distribution channel: Hospitals pharmacy, Retail pharmacy, Online sales
  5. By Geography: North America, Europe, Asia-Pacific, Rest of the world
  6. By Type of Psittacosis: Ornithosis, Parrot fever, Chlamydiosis


Psittacosis Treatment Challenges

There are several challenges facing the Psittacosis treatment market.

  1. Limited number of effective treatments: Currently, there are few FDA-approved treatments for psittacosis, which can make it difficult for physicians to effectively manage the disease.
  2. Difficulty in diagnosis: Psittacosis can be difficult to diagnose as its symptoms are similar to those of other respiratory infections, which can lead to misdiagnosis and delayed treatment.
  3. Lack of awareness: Many people are not aware of the disease and its symptoms, which can lead to delayed diagnosis and treatment.
  4. Limited research: There is a lack of research on psittacosis, which makes it difficult to develop new treatments and improve existing ones.
  5. High cost: The treatment of psittacosis can be costly, which can make it difficult for individuals without insurance or those with high-deductible plans to afford.


Psittacosis Treatment Market Key Players

There are several key players in the psittacosis treatment market, including:

  1. Pfizer Inc.
  2. Novartis AG
  3. GlaxoSmithKline plc.
  4. Merck & Co., Inc.
  5. Sanofi
  6. AstraZeneca
  7. Takeda Pharmaceutical Company Limited
  8. Teva Pharmaceutical Industries Ltd
  9. Mylan N.V.
  10. Aurobindo Pharma Limited


Psittacosis is a disease caused by a bacterial infection called Chlamydia psittaci. It is also known as parrot fever, ornithosis, and chlamydiosis.

Symptoms of psittacosis include fever, chills, headache, muscle aches, and a dry cough. Some people may also experience pneumonia, which can be severe.

Psittacosis is treated with antibiotics such as doxycycline, azithromycin, and erythromycin. Treatment usually lasts for at least one to two weeks.

Psittacosis is usually transmitted to humans through the droppings or respiratory secretions of infected birds, especially parrots, parakeets, and macaws.

Due to the fact that psittacosis is a rare infection and the market for its treatment is relatively small and niche, the global market size data for this infection is not significant, and can be treated with several combinations of antibiotics.

Some of the key players in the psittacosis treatment market are Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Merck & Co., Inc., Sanofi, AstraZeneca, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Mylan N.V., Aurobindo Pharma Limited.

Custom Research Requirement? Questions to ask?

Get in touch

Custom Research requirement.

Go Up